GlaxoSmithKline will extend a trial testing an experimental rheumatoid arthritis drug on patients suffering from pneumonia related to Covid-19 to focus on the elderly as the company seeks to firm up encouraging findings.
Bay Area-based Genentech launched a new study assessing the company’s rheumatoid arthritis drug Actemra as a potential treatment for COVID-19 with an eye toward increasing diversity and inclusion among patients treated.
Regeneron Pharmaceuticals will repurchase about $5 billion of the U.S. drugmaker’s shares directly from France’s Sanofi, without altering their 17-year partnership.
Sanofi and Regeneron Pharmaceuticals expanded a clinical trial of the companies’ rheumatoid arthritis drug Kevzara as a coronavirus treatment to patients outside the United States.
A U.S. judge upheld two patents relating to Amgen Inc.’s blockbuster rheumatoid arthritis drug Enbrel, denying a challenge by Novartis AG, which is seeking to launch a copycat version.
In 2015, Pfizer researchers were analyzing hundreds of thousands of insurance claims and noted that patients receiving the company’s anti-inflammatory Enbrel appeared to have a reduced risk of Alzheimer’s disease – by a startling 64 percent.
